Results 271 to 280 of about 1,755,661 (359)

Clinical and economic impacts of a clinical pathway-based single disease payment policy on hysterectomy for uterine fibroids: a decade-long interrupted time series analysis. [PDF]

Front Public Health
Zheng H, Li Z, Lin H, Yi H, Zheng X.
europepmc   +1 more source

Policy Levers for First-Contact Healthcare Provider Choice: A Discrete Choice Experiment in Shanghai's Hierarchical Medical System. [PDF]

Appl Health Econ Health Policy
Gong Y.
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Recent Developments in United States Vaccine Policy: A Narrative Review. [PDF]

Dela J Public Health
Bhatt S, Smith K.
europepmc   +1 more source

Measuring the Impact: Magnetic Resonance Imaging Response of Sacroiliac Joints to Tumor Necrosis Factor Inhibitors in Youth With Axial Disease

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes (PROs) in youth with axial juvenile spondyloarthritis (axJSpA) initiating tumor necrosis factor inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

NHS Consultants and Their Use of Private Medical Insurance. [PDF]

Cureus
Nightingale C.
europepmc   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Brown crusts on infant owing to contact dermatitis associated with ethanol disinfection

Journal of General and Family Medicine
Yuki Matsuhisa, Tsuneaki Kenzaka, Hideo Hirose, Tadao Gotoh   +3 more
doaj   +1 more source

Examining the potential of mobile money-based health insurance for people living with HIV and hypertension or diabetes in Uganda. [PDF]

Front Health Serv
Zakumumpa H, Ssempala R, Kiplagat J, Kwiringira J, Quentin W, Struckmann V.   +5 more
europepmc   +1 more source

Insurance and Awareness: A cross-sectional Study on Awareness of Health Insurance, Covering Physiotherapy Treatment Among General Population and Physiotherapists

Smati Sambyal, Sandeep Kumar, Harmandeep Kaur, Mohit Kumar, Kumari Manisha   +4 more
openalex   +2 more sources